Mateon Therapeutics team publishes three new peer-reviewed oncology articles outlining the clinical impact potential of its ﬁrst-in-class anti-TGF-beta RNA therapeutic OT101/trabedersen

trabedersen (OT-101) - Autotelic, Mateon Therapeutics

Dec 2, 2019